Artificial pancreas ‘superior’ in young children with Type 1 diabetes

A 13-week trial has found that a hybrid closed-loop automated insulin delivery system improved time-in-range for blood glucose compared with standard care for children with Type 1 diabetes.

Type 1 diabetes treatment is particularly challenging in children younger than 6 because of their small insulin dosing requirements and unpredictable eating and activity habits.

In this study of 102 children with Type 1 diabetes aged at least 2 years but younger than 6 years, the hybrid closed-loop system (also called automated insulin delivery or artificial pancreas) used was comprised of a t:slim X2 insulin pump, a Dexcom G6 continuous glucose monitor (CGM), and Control-IQ technology system algorithm software (Tandem Diabetes Care).

In this study, time-in-range over 13 weeks was higher for those randomized to the hybrid closed-loop system compared with standard of care; the latter included either an insulin pump or multiple daily injections plus a separate Dexcom G6 CGM. The hybrid closed-loop system added an average of about 3 hours in ideal blood glucose range over the 13 weeks, compared to no change with standard care.

To read more, CLICK HERE and here.


Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags